Leukemia Research
Volume 28, Issue 3 , Pages 243-248 , March 2004

All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells

  • O Bairey

      Affiliations

    • Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel
    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-3-937-8202/05/00; fax: +972-3-924-0145.
    • ,
  • O Boycov

      Affiliations

    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Institute of Pathology, Rabin Medical Center, Beilinson Campus, Petah Tikva 49100, Israel
    • ,
  • E Kaganovsky

      Affiliations

    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Institute of Pathology, Rabin Medical Center, Beilinson Campus, Petah Tikva 49100, Israel
    • ,
  • Y Zimra

      Affiliations

    • Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel
    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • M Shaklai

      Affiliations

    • Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel
    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • E Rabizadeh

      Affiliations

    • Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel
    • The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Received 27 March 2003 ,Accepted 1 July 2003.

References 

  1. Reed JC. Molecular biology of chronic lymphocytic leukemia: implication for therapy. Semin. Haematol. 1998;35:3–13
  2. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer. Res. 2000;60:293–312
  3. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the anti-apoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998;273:13313–13316
  4. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)- mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 1999;154:375–384
  5. Chen H, Treweeke AT, West DC, Kathleen JT, Cawley JC, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181–3187
  6. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukemia. Br. J. Haematol. 2001;113:400–406
  7. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. 2000;26:561–569
  8. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelium growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 2000;34:185–194
  9. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;1:5598–5605
  10. Ziegler BL, Valtieri M, Almeida Porada G, De Maria R, Muller R, Masella B, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999;285:1553–1558
  11. Cheson BD, Bennett JM, Grever M, Kay N, Keating JM, O’Brien S, et al. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia-revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  12. Rai K, Sawitsky A, Cronkite E, Chanana AD, Levy RN, Pasternak B. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  13. Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblast growth factor in early B-cell chronic lymphocytic leukemia. Br. J. Cancer. 2002;86:31–35
  14. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002;100:3344–3351
  15. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002;16:911–919
  16. Aguayo A, Manshouri T, O’Brien S, Keating M, Beran M, Koller C, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk. Res. 2001;25:279–285
  17. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O’Brien S, Lerner S, et al. High levels of vascular endothelial growth factor receptor-2 correlates with shortened survival in chronic lymphocytic leukemia. Clin. Cancer Res. 2001;7:795–799
  18. Gitay Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 1993;190:702–708
  19. Takanami I, Tanaka F, Hashizume T, Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997;17:2811–2814
  20. Boocock CA, Chamock Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors Flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. 1995;87:506–516
  21. De Jong JS, Van Diest PJ, Van Der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I. An inventory in search of autocrine and paracrine loops. J. Pathol. 1998;184:44–52
  22. Carroll RS, Zhang J, Bello L, Melnick MB, Maruyama T, McL Black P. KDR activation in astrocytic neoplasm. Cancer. 1999;86:1335–1341
  23. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Horsfall DJ, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 2002;62:854–859
  24. Dias S, Hattoti K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10857–10882
  25. Leenders WOJ. Targeting VEGF anti-angiogenic and anti-tumour therapy: where are we now?. Int. J. Exp. Pathol. 1998;79:339–346

PII: S0145-2126(03)00256-X

doi: 10.1016/S0145-2126(03)00256-X

Leukemia Research
Volume 28, Issue 3 , Pages 243-248 , March 2004

Article Tools

* Image Usage & Resolution